Aquestive Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aquestive Therapeutics Inc 's ROA in the second quarter of 2026?
Aquestive Therapeutics Inc recorded a cumulative net loss of $-78 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -49.63%.

However, within the Healthcare sector 575 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3918, from total ROA ranking in the first quarter of 2026 at 4748.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	79.64 %	38.04 %	65.35 %	52.34 %	-17.03 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-78	-69	-84	-69	-65
Return On Assets (TTM)	-49.63 %	-49.59 %	-64.83 %	-60.84 %	-65.31 %
AQST's Total Ranking	# 3918	# 4748	# 4126	# 4229	# 4158
Total Assets (TTM) in million	168	141	160	161	94
Seq. Total Assets Change	19.27 %	-12.03 %	-0.1 %	71.39 %	-8.35 %
Seq. Net Income Change	-	-	-	-	-

AQST's 5 Years Annual ROA >> Back to AQST Management Effectiveness >> Compare AQST ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 252
Sector	# 576
Overall	# 3922

Return On Assets Statistics
High	Average	Low
-13.39 %	-65.94 %	-133.14 %
(Dec 31 2023)		(Mar 31 2019)

News about Aquestive Therapeutics Inc Return on Assets ROA

Navigating Innovation and Financial Turbulence: Aquestive Therapeutics Aims for a Breakthrough in Allergy and Epilepsy Treatment

In the fast-paced world of pharmaceuticals, where innovation often dances on the precipice of financial stability, Aquestive Therapeutics Inc. (NASDAQ: AQST) stands at a crossroads. As the company prepares to unveil new findings on its investigational drug, Anaphylm—an epinephrine sublingual film aimed at combating severe allergic reactions, including anaphylaxis—their narrative is twofold: a commitment to groundbreaking science intertwined with significant financial challenges. A Groundbreaking Approach to Allergy ManagementScheduled for presentation at the 2025 American Academy of Allergy, Asthma and Immunology (AAAAI) Annual Meeting in San Diego from February 28 to March 3, 2025, Aquestive s Anaphylm represents a potential game-changer in the management of severe allergic reactions. Traditional methods of administering epinephrine often involve injections, a method that can be intimidating for patients, particularly children. By utilizing a sublingual film that dissolves under the tongue, Aquestive aims to provide a more user-friendly and efficient alternative.

Headlining Innovation Amid Losses: Aquestive Therapeutics Charts 2025 Course with Focus on Pediatric Epilepsy Solutions

As 2025 unfolds, a spotlight shines on Aquestive Therapeutics Inc. (NASDAQ: AQST), a Warren, N.J.-based pharmaceutical company currently navigating both turbulent fiscal waters and vital advancements in pediatric neurology. The firm recently shared a multi-faceted business update underscoring its commitment to innovative drug delivery platforms and focused objectives. However, the backdrop to these ambitions is a concerning financial picture characterized by significant losses and mounting challenges.In its announcement dated January 13, 2025, Aquestive revealed a cumulative net loss of $35 million for the 12 months ending in the third quarter of 2024. This staggering deficit corresponds to a negative return on assets (ROA) of -35.51%. Such financial statistics raise critical questions about the company’s operational viability and long-term sustainability. Investors historically look to ROA as a crucial indicator of how effectively a company generates profits relative to its total assets. A negative figure, particularly at this magnitude, signals deeper issues that may hinder growth prospects.

Financial Statements
Aquestive Therapeutics Inc 's Assets	$ 168 million	AQST's Balance sheet
Aquestive Therapeutics Inc 's Income	$ -23 million	Quarterly AQST's Income Statement
AQST's Income by Division		See AQST's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	65.35 %	81.61 %	0.03 %	-10.03 %	-33.03 %
Total Assets in million	160	97	53	53	59
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-84	-44	-8	-54	-71
Annual Return On Assets	-52.23 %	-45.49 %	-14.73 %	-101.88 %	-118.82 %

AQST's 5 Years Annual ROA >> Back to AQST Management Effectiveness >> Compare AQST ROA to its Competitors

More Return On Assets Ratios
AQST's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AQST's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AQST's Competitors
Subscribers only: Roa for Aquestive Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for AQST's Customers

You may also want to know
AQST's Roi	AQST's Inventory Turnover Ratio	AQST's Growth Rates	AQST's Dividend Comparisons
	AQST's Profitability Ratios	AQST's Asset Turnover Ratio	AQST's Dividend Growth
AQST's Roe	AQST's Valuation Ratios	AQST's Financial Strength Ratios	AQST's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-26T07:39:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.